Almirall Agrees Aclidinium Licensing Deal With Menarini Biotech

Almirall has granted Menarini marketing rights to Aclidinium for the treatment of chronic obstructive pulmonary disease (COPD) in Europe. Under the terms of the deal, Menarini will have joint commercialisation rights to the drug across the majority of EU member states and in other European countries. Almirall will retain sole marketing rights for the product in the UK, the Netherlands and the Nordic countries. Eduardo Sanchiz, chief executive officer of Almirall, explained that Menarini "stood out" among a number of potential partners for the licensing agreement.

Back to news